Premium
Effect of retinoic acid on tumor‐mediated immunologic alterations in mice bearing a variant of the ß16 melanoma
Author(s) -
Jiang Cheng Gan,
Taylor Douglas D.,
Black Paul H.
Publication year - 1990
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910460618
Subject(s) - retinoic acid , cd8 , in vivo , population , in vitro , melanoma , concanavalin a , tretinoin , lymphocyte , endocrinology , medicine , immunology , cancer research , chemistry , immune system , biology , cell culture , biochemistry , genetics , microbiology and biotechnology , environmental health
This investigation examined the effect of retinoic acid on tumor progression and immunological status of mice bearing the B16‐F10 melanoma (previously selected for high lungcolonizing capacity). Tumor cells were implanted s. c. in syngeneic C57BL/6 mice, half of which were treated with β‐all trans retinoic acid (RA). Although RA failed to exhibit direct toxicity on this variant at the concentration used, the immunologic aberrations induced by the tumors were diminished by i. p. RA administration (at45μ twice/week for 3 weeks). In mice bearing B16‐F10 tumors, tumor burdens were decreased from 2.9% of body weight to 1.6%. The mitogenic responses of splenic lymphocytes to concanavalin A (ConA) were increased in tumor‐bearing mice following this RA treatment. The presence of these tumor cells decreased the absolute number of CD4‐ and CD8‐positive splenic lymphocytes. Following RA treatment, the CD8‐positive population was increased in tumor‐bearing mice, while the CD + population was not significantly altered. Since previous studies indicated that plasma membrane fragments (or vesicles) could alter lymphocyte distributions and proliferative capacities, the in vitro shedding of membrane fragments from B16‐F10 tumor cells was assayed and observed to be decreased after continuous treatment of cultures with 10 −6 M RA for 21 days. Membrane shedding from B16‐F10 cells was inhibited by 48.5% following RA treatment. Based on these in vivo and in vitro results, we suggest that RA treatment may diminish tumor growth by decreasing tumor‐induced immunosuppressive events.